Results 81 to 90 of about 38,393 (221)

Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study [PDF]

, 2016
OBJECTIVE: To investigate trends in incident and prevalent diagnoses of type 2 diabetes mellitus (T2DM) and its pharmacological treatment between 2000 and 2013. DESIGN: Analysis of longitudinal electronic health records in The Health Improvement Network (
Nazareth, I, Petersen, I, Sharma, M
core   +1 more source

Antiatherogenic Effects of Thiazolidinediones? [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2001
Treatment of type 2 diabetes mellitus (DM) is directed at relieving symptoms of hyperglycemia and reducing the incidence of diabetes-associated pathologies. Complications of atherosclerosis, including myocardial infarction and stroke, are the most common causes of death in diabetic patients.
openaire   +2 more sources

Diabetes management in people undergoing metabolic‐bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) Group

Diabetic Medicine, EarlyView.
Abstract The global prevalence of obesity and diabetes continues to rise, with metabolic‐bariatric surgery recognised as an effective intervention for obesity and type 2 diabetes, offering potential for type 2 diabetes remission and improved glycaemic control. This guideline, developed by the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP)
Jeffrey W. Stephens, Ketan Dhatariya, Andrew J. Beamish, Dimitri J. Pournaras, Alexander D. Miras, Nader Raafat, Georgia Noble‐Bell, Rachel Cadwallader Buckland, Omar G. Mustafa   +8 more
wiley   +1 more source

Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation [PDF]

, 2013
AMPK (AMP-activated protein kinase) is a key regulator of cellular and whole-body energy balance. AMPK phosphorylates and regulates many proteins concerned with nutrient metabolism, largely acting to suppress anabolic ATP-consuming pathways while ...
Ahmadian, An, Anthony, Arita, Arkan, Bain, Barnes, Barré, Bauwens, Berggreen, Bourron, Boyle, Boyle, Brooks, Buhl, Carey, Carling, Carling, Caton, Chakrabarti, Chaves, Chavez, Chen, Chen, Cheung, Cinti, Cool, Coppari, Daval, Daval, Ducharme, Duncan, Dzamko, Egan, Emerling, Eringa, Fazakerley, Fischer, Fisher, Flechtner-Mors, Foretz, Fox, Fryer, Gaidhu, Gaidhu, Gaidhu, Gaidhu, Galic, Garton, Gauthier, Gauthier, Geraghty, Giri, Glass, Grimaldi, Guigas, Gurriarán-Rodríguez, Gustafson, Habinowski, Hardie, Hawley, Hawley, Hawley, Henin, Hevener, Holmes, Hutchinson, Huypens, Ian P. Salt, Iglesias, Imamura, Iwatsubo, Jeon, Jeong, Jiao, Kanda, Kelly, Kim, Kitade, Koh, Kohlstedt, Koistinen, Kola, Kou, Kramer, Kristensen, Lee, Lee, Li, Lihn, Lihn, Lin, Lin, Liu, Lorente-Cebrián, Luo, López, Lönnqvist, MacDougald, Martínez-Agustin, Marzolla, McBride, McGee, McInnes, McInnes, Minokoshi, Mulligan, Narkar, Nguyen, Nishimura, Nishimura, Odegaard, Ojuka, Ojuka, Orci, Pagnon, Park, Peng, Perrotti, Peyton, Polakof, Pulinilkunnil, Rasmussen, Reihill, Reshef, Reshef, Rosen, Saberi, Sag, Sakamoto, Sakamoto, Sakaue, Sakoda, Salt, Salt, Salt, Samovski, Sano, Sarah J. Mancini, Schwenk, Scott, Shi, Silvia Bijland, Solinas, Sponarova, Steinberg, Steinberg, Su, Sullivan, Sun, Takekoshi, Tam, Tang, Turer, Vandanmagsar, Vats, Vaughan, Vila-Bedmar, Villena, Vingtdeux, Viollet, Vucetic, Wan, Wang, Wang, Wang, Watt, Winder, Woods, Wu, Xiao, Xu, Yamauchi, Yang, Yin, Yuen, Zhang, Zhang, Zhang, Zhang, Zhou, Zimmermann, Zmijewski   +182 more
core   +1 more source

Real‐world treatment trajectories preceding GLP‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
Franziska S. Ulrich, Morten Frost Nielsen, Nicola Napoli, Andrea M. Burden   +3 more
wiley   +1 more source

Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus

Терапевтический архив, 2012
Aim. To evaluate the efficiency and safety of early combination therapy with sulfonylurea derivatives (SUD) and insulin sensitizers in patients with type 2 diabetes mellitus (T2DM). Subjects and methods.
O N Goncharenko, A S Ametov, M R Isakova
doaj  

Noninsulin pharmacological management of type 1 diabetes mellitus

Indian Journal of Endocrinology and Metabolism, 2011
The injectable nature and other shortcomings of insulin have stimulated interest in studying the noninsulin pharmacological therapies to manage type 1 diabetes mellitus (T1DM).
Vishvas Garg
doaj   +1 more source

Hepatic and abdominal adiposity in type 2 diabetes as assessed with machine learning on computed tomography scans

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The combined assessment of multiple abdominal imaging traits in relation to type 2 diabetes remains incompletely characterised. The study examines these relationships on computed tomography (CT) scans from a large‐scale, racially diverse, disease‐focused medical biobank.
Richard H. Tran, Pavan Raghupathy, Mohamad Hazim, Elizabeth Thompson, Sophia Swago, Abhijit Bhattaru, Matthew MacLean, Jeffrey T. Duda, James Gee, Charles Kahn Jr., Daniel J. Rader, Arijitt Borthakur, Walter R. Witschey, Hersh Sagreiya   +13 more
wiley   +1 more source

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas

Clinical and Translational Science
The risk of psoriasis in diabetic patients has rarely been explored. This study aims to compare the risk of incident psoriasis in patients with Type 2 diabetes (T2D) who initiate dipeptidyl peptidase‐4 inhibitors (DPP‐4is) or thiazolidinediones (TZDs ...
Wei‐Sheng Chen, Tzu‐Min Lin, Yu‐Sheng Chang, Yu‐Chuan Shen, Hui‐Ching Hsu, Tzu‐Tung Kuo, Shu‐Chuan Chen, Jin‐Hua Chen, Chi‐Ching Chang   +8 more
doaj   +1 more source

Ciglitazone-a human PPARγ agonist-disrupts dorsoventral patterning in zebrafish. [PDF]

, 2019
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor that regulates lipid/glucose homeostasis and adipocyte differentiation.
Cheng, Vanessa, Dasgupta, Subham, Reddam, Aalekhya, Volz, David C   +3 more
core